Vernakalant

Summary

Vernakalant (CHEMBL2111112) is an approved small molecule (ATC C01BG11); indicated across 3 conditions including atrial fibrillation and atrial flutter.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01BG11
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 349.5 Da · C20H31NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111112
Name	Vernakalant
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9930049
ATC	C01BG11
Molecular formula	C20H31NO4
Molecular weight	349.5
InChIKey	VBHQKCBVWWUUKN-KZNAEPCWSA-N

SMILES: COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC

IUPAC name: (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol

Also known as: Vernakalant, VERNAKALANT, vernakalant, Vernakalant (Hydrochloride)

Parent form; salt/anhydrous children: CHEMBL2107383

Patent coverage: 96 distinct patent families (262 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Sodium-dependent serotonin transporter.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A4	5.98	AC50	1040	nM	CHEMBL_ACT_25151846

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atrial fibrillation	3	MONDO:0004981	EFO:0000275
atrial flutter	2	MONDO:0005310	EFO:0003911

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01627106	PHASE4	WITHDRAWN	A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)
NCT01646281	PHASE4	UNKNOWN	Vernakalant Versus Flecainide: Atrial Contractility
NCT03005366	PHASE4	COMPLETED	Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents
NCT04485195	PHASE4	COMPLETED	RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
NCT04748991	PHASE3	NOT_YET_RECRUITING	Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
NCT00668759	PHASE3	COMPLETED	A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation
NCT00989001	PHASE3	TERMINATED	A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
NCT01370629	Not specified	COMPLETED	Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).